Decoy Therapeutics Inc. (DCOY)
Oxford Ledge is still expanding full research coverage of DCOY. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Pre-clinical biotech company developing peptide conjugate therapeutics through an AI-enabled platform, with no approved products.
SEC filings
- S-1 IPO / securities registration statement 2026-07-10
- 8-K Entry into material agreement; 3.02; Regulation FD disclosure; Financial statements and exhibits 2026-06-29
- S-1 IPO / securities registration statement 2026-06-15
- DEF 14A Proxy statement for shareholder vote 2026-06-04
- 8-K 5.08; Other material event 2026-05-19
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for DCOY. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open DCOY in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.